Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Trimethylaminuria is a rare metabolic disorder that is associated with abnormal amounts of the dietary-derived trimethylamine. Excess unmetabolized trimethylamine in the urine, sweat and other body secretions confers a strong, foul body odor that can affect the individual's ability to work or engage in social activities. This review summarizes the biochemical aspects of the condition and the classification of the disorder into: 1) primary genetic form, 2) acquired form, 3) childhood forms, 4) transient form associated with menstruation, 5) precursor overload and 6) disease states. The genetic variability of the flavin-containing monooxygenase (form 3) that is responsible for detoxication and deodoration of trimethylamine is discussed and put in context with other variant forms of the flavin-containing monooxygenase (forms 1-5). The temporal-selective expression of flavin-containing monooxygenase forms 1 and 3 is discussed in terms of an explanation for childhood trimethylaminuria. Information as to whether variants of the flavin-containing monooxygenase form 3 contributes to hypertension and/or other diseases are presented. Discussion is provided outlining recent bioanalytical approaches to quantify urinary trimethylamine and trimethylamine N-oxide and plasma choline as well as data on self-reporting individuals tested for trimethylaminuria. Finally, trimethylaminuria treatment strategies and nutritional support are described including dietary sources of trimethylamine, vitamin supplementation and drug treatment and issues related to trimethylaminuria in pregnancy and lactation are discussed. The remarkable progress in the biochemical, genetic, clinical basis for understanding the trimethylaminuria condition is summarized and points to needs in the treatment of individuals suffering from trimethylaminuria.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“humans with genetic defects in FMO3 suffer from Fish Odor Syndrome due to the accumulation of TMA and its noxious odor”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Cashman et al., 2003
Citations
Cites
Physiology, biochemistry, and molecular biology of the skin
Goldsmith, L. A. (1991) · Oxford University Press eBooks · Cited by 448
Bad Breath—Research Perspectives
Rosenberg, M., & Doyle, R. J. (1995) · Journal of Dental Research · doi:10.1177/00220345950740051501 · Cited by 119
Trimethylamine and Foetor Hepaticus
Mitchell, S. C. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750026281 · Cited by 46
Self-citation
Cited by
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
“It is also well established that humans with genetic defects in FMO3 suffer from fish odor syndrome, due to the accumulation of TMA and its noxious odor (Cashman et al., 2003), reducing the appeal of FMO3 as a potential therapeutic target for inhibition.”
BackgroundRole of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
Krueger, S. K., & Williams, D. E. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.001 · Cited by 567
“A number of allelic variants have been associated with the incidence and severity of TMAU in patients (Zhang et al., 1996, 2003; Cashman et al., 1997, 2000, 2001, 2003; Dolphin et al., 1997; Kang et al., 2000; Murphy et al., 2000; Forrest et al., 2001; Cashman, 2002; Cashman & Zhang, 2002; Park et…”
BackgroundHUMAN FLAVIN-CONTAINING MONOOXYGENASES
Cashman, J. R., & Zhang, J. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141043 · Cited by 333
Self-citationProbiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders
Yoo, J., & Kim, S. (2016) · Nutrients · doi:10.3390/nu8030173 · Cited by 328
“TMAO, an oxidation product of trimethylamine (TMA), is a relatively common metabolite of choline in animals [35].”
BackgroundGut microbiota in atherosclerosis: focus on trimethylamine N‐oxide
Zhu, Y., Li, Q., & Jiang, H. (2020) · APMIS · doi:10.1111/apm.13038 · Cited by 196
“laminuria, also known as fish malodor syndrome (91, 92).”
BackgroundHines, R. N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.05.079 · Cited by 190
“As a result, trimethylamine is excreted n the urine, breath, and sweat, often resulting in social ostracism Cashman et al., 2003).”
BackgroundSelf-citationHernandez, D., Janmohamed, A., Chandan, P., Phillips, I. R., & Shephard, E. A. (2004) · Pharmacogenetics · doi:10.1097/00008571-200402000-00006 · Cited by 173
New insights into the mechanisms of high‐fat diet mediated gut microbiota in chronic diseases
Chen, J., Xiao, Y., Li, D., Zhang, S., Wu, Y., Zhang, Q., & Bai, W. (2023) · iMeta · doi:10.1002/imt2.69 · Cited by 161
“TMAO is an oxidation product metabolized by the metabolite trimethy-lamine of intestinal microbial through liver flavin ‐ containing monooxygenase 3 (FMO3) [89].”
BackgroundFlavin-containing monooxygenases: mutations, disease and drug response
PHILLIPS, I., & SHEPHARD, E. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.004 · Cited by 139
Nicholson, G., Rantalainen, M., Li, J. V., Maher, A. D., Malmodin, D., Ahmadi, K. R., Faber, J. H., Barrett, A., Min, J. L., Rayner, N. W., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002270 · Cited by 137
“Trimethylamine N-oxide (TMAO) is formed endogenously in the liver via the Noxygenation of TMA by the flavin-containing monooxygenase (FMO) protein family, and particularly by FMO3 [47].”
BackgroundSome distinctions between flavin-containing and cytochrome P450 monooxygenases
Cashman, J. R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.009 · Cited by 130
Self-citationBerberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice
Shi, Y., Hu, J., Geng, J., Hu, T., Wang, B., Yan, W., Jiang, Y., Li, J., & Liu, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.148 · Cited by 111
Fishy taint in chicken eggs is associated with a substitution within a conserved motif of the gene
Honkatukia, M., Reese, K. R., Preisinger, R., Tuiskula-Haavisto, M., Weigend, S., Roito, J., Mäki‐Tanila, A., & Vilkki, J. (2005) · Genomics · doi:10.1016/j.ygeno.2005.04.005 · Cited by 118
“In humans, 12 missense mutations, 3 nonsense mutations, and 1 deletion of FMO3 are currently known to cause TMAuria [11,12].”
BackgroundHuman Breath Odors and Their Use in Diagnosis
WHITTLE, C. L., Fakharzadeh, S. S., Eades, J., & Preti, G. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1384.011 · Cited by 108
Self-citationTrimethylaminuria: causes and diagnosis of a socially distressing condition.
Mackay, R. J., McEntyre, C. J., Henderson, C., Lever, M., & George, P. M. (2011) · Europe PMC (PubMed Central) · Cited by 128
Role of flavin-containing monooxgenase in drug development
Cashman, J. R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802522188 · Cited by 79
“Unlike the oxidative portion of the half reaction, where it is clear that FMO3 is solely responsible for formation of TMA N-oxide, the nature of the catalyst(s) that forms the retro-reduction product TMA is unknown [42] .”
BackgroundSelf-citationA review of trimethylaminuria: (fish odor syndrome).
Messenger, J., Clark, S. M., Massick, S. C., & Bechtel, M. A. (2013) · Europe PMC (PubMed Central) · Cited by 114
Yamazaki, H., Fujieda, M., Togashi, M., Saito, T., Preti, G., Cashman, J. R., & Kamataki, T. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.10.022 · Cited by 81
“Trimethylaminuria (TMAU), or fish-like odor syndrome, is a genetic disease characterized by excretion of trimethylamine (TMA) (Al Waiz et al., 1987; Ayesh et al., 1993; Cashman et al., 2003).”
BackgroundResultInfluentialSelf-citationCashman, J. R. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03136-8 · Cited by 72
Self-citationLattard, V., Zhang, J., Tran, Q., Furnes, B., Schlenk, D., & Cashman, J. R. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.854 · Cited by 71
“Recently, two African-American individuals were identified as possessing the His132-FMO3 variant (Cashman et al., 2003).”
BackgroundSelf-citationFunctional characterization of genetic variants of human FMO3 associated with trimethylaminuria
Yeung, C. K., Adman, E. T., & Rettie, A. E. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.04.014 · Cited by 68
“Distressingly for TMAU sufferers, the unmetabolized trimethylamine is excreted in the sweat and exhaled breath, resulting in a characteristic fish-odor [12].”
BackgroundTrimethylamine emissions in animal husbandry
Sintermann, J., Schallhart, S., Kajos, M. K., Jocher, M., Bracher, A., Münger, A., Johnson, D., Neftel, A., & Ruuskanen, T. M. (2014) · Biogeosciences · doi:10.5194/bg-11-5073-2014 · Cited by 68
“Main pathways of TMA and NH3 production by the ruminant system (with the focus on TMA). man urine is, for example, used as a diagnostic tool for a disturbed metabolism (Cashman et al., 2003; Lee et al., 2010).”
BackgroundExploring the biocatalytic scope of a bacterial flavin-containing monooxygenase
Rioz‐Martínez, A., Kopacz, M., de Gonzalo, G., Pazmiño, D. E. T., Gotor, V., & Fraaije, M. W. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00988a · Cited by 65
Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry.
Martin, E. A., Brown, K., Gaskell, M., Al‐Azzawi, F., Garner, R. C., Boocock, D. J., Mattock, E., Pring, D. W., Dingley, K. H., Turteltaub, K. W., et al. (2003) · PubMed · Cited by 64
Balancing the Equation: A Natural History of Trimethylamine and Trimethylamine-N-oxide
Loo, R. L., Chan, Q. M., Nicholson, J. K., & Holmes, E. C. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00851 · Cited by 65
Busby, M. G., Fischer, L. M., da Costa, K.-A., Thompson, D., Mar, M.-H. H., & Zeisel, S. H. (2004) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.09.027 · Cited by 69
Koukouritaki, S. B., & Hines, R. N. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.8.807 · Cited by 60
Self-citationThe Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease
Hage, R. E., Al-Arawe, N., & Hinterseher, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032399 · Cited by 62
“FMO3 is an enzyme in the liver that is reported to convert TMA into TMAO, and the inhibition of this enzyme would lead to the accumulation of TMA in the gut, which would cause trimethylaminuria, also known as fish malodor syndrome [195,196].”
BackgroundTreatments of trimethylaminuria: where we are and where we might be heading
Schmidt, A. C., & Leroux, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.026 · Cited by 64
Flavin-containing monooxygenase 3 and human disease
Motika, M. S., Zhang, J., & Cashman, J. R. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.831 · Cited by 53
“Expert opinion Flavin-containing monooxygenase 3 and human disease Meike S Motika , Jun Zhang & John R Cashman † Human Biomolecular Research Institute , 5310 Eastgate Mall , San Diego, CA 92121 , USA This review summarizes information concerning the association of the human flavin-containing monooxygenase 3 (FMO3) and…”
BackgroundInfluentialSelf-citationDisposition and Metabolite Kinetics of Oral L‐carnitine in Humans
Bain, M. A., Milne, R. W., & Evans, A. M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006292851 · Cited by 47
Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis
Jang, J. W., Capaldi, E., Smith, T. L., Verma, P., Varga, J., & Ho, K. J. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00895-8 · Cited by 54
“(Cashman et al. 2003) Targeting TMA lyase activity in gut microbiota is another exciting strategy that appears to have potential as a clinical tool.”
Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3
Hines, R. N. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.1.41 · Cited by 42
“Subsequent studies provided definitive evidence that relatively rare mutations, specifically in FMO3, are the major cause of this disorder (reviewed in [62]).”
BackgroundSelf-citationDimethylsulphidemia: the significance of dimethyl sulphide in extra-oral, blood borne halitosis
Harvey-Woodworth, C. N. (2013) · BDJ · doi:10.1038/sj.bdj.2013.329 · Cited by 40
Yamazaki, H., Fujita, H., Gunji, T., Zhang, J., Kamataki, T., Cashman, J. R., & Shimizu, M. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.08.008 · Cited by 40
Self-citationMotika, M. S., Zhang, J., Zheng, X., Riedler, K., & Cashman, J. R. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.02.006 · Cited by 40
“to generally decrease FMO3 activity when observed together [6,14,24].”
BackgroundInfluentialSelf-citationEsposito, T., Varriale, B., D’Angelo, R., Amato, A., & Sidoti, A. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0012 · Cited by 46
Clinical utility gene card for: Trimethylaminuria – update 2014
Shephard, E. A., Treacy, E. P., & Phillips, I. R. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.226 · Cited by 39
Calenic, B., & Amann, A. (2014) · Bioanalysis · doi:10.4155/bio.13.306 · Cited by 37
Rendic, S. P., Crouch, R. D., & Guengerich, F. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03304-3 · Cited by 37
Hai, X., Konečnỳ, J., Zeisbergerová, M., Adams, E., Hoogmartens, J., & Schepdael, A. V. (2008) · Electrophoresis · doi:10.1002/elps.200800138 · Cited by 34
Flavin Containing Monooxygenases and Metabolism of Xenobiotics
Başaran, R., & Eke, B. C. (2017) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.30592 · Cited by 34
Rox, K., Rath, S., Pieper, D. H., Vital, M., & Brönstrup, M. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.03.007 · Cited by 34
“Thi hepatic flavin monooxygenase 3 to TMAO [7].”
BackgroundHai, X., Adams, E., Hoogmartens, J., & Schepdael, A. V. (2009) · Electrophoresis · doi:10.1002/elps.200800604 · Cited by 31
Jiang, C., Wang, S., Wang, Y., Wang, K., Huang, C., Gao, F., Hu, H., Deng, Y., Zhang, W., Zheng, J., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155349 · Cited by 34
Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut–Heart Axis
Matsiras, D., Bezati, S., Ventoulis, I., Verras, C., Parissis, J., & Polyzogopoulou, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072567 · Cited by 39
Individuals Reporting Idiopathic Malodor Production: Demographics and Incidence of Trimethylaminuria
Wise, P. M., Eades, J., Tjoa, S., Fennessey, P. V., & Preti, G. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.05.030 · Cited by 31
“Trimethylaminuria is difficult to diagnose because symptoms can be sporadic and variable in intensity because they are associated with dietary composition.(4,7,8) Further, as we ecently showed, symptoms reported during patient presenations are diverse.”
BackgroundInfluentialSelf-citationShimizu, M., Allerston, C. K., Shephard, E. A., Yamazaki, H., & Phillips, I. R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12240 · Cited by 27
Liu, S., Bennett, D. C., Tun, H. M., Kim, J.-E., Cheng, K. M., Zhang, H., & Leung, F. C.-C. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01092 · Cited by 26
Abdelhameed, M., Karsenti, P., Langlois, A., Lefebvre, J., Richeter, S., Ruppert, R., & Harvey, P. D. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201403146 · Cited by 22
D’Angelo, R., Esposito, T., Calabrò, M., Rinaldi, C., Robledo, R., Varriale, B., & Sidoti, A. (2012) · Gene · doi:10.1016/j.gene.2012.12.047 · Cited by 25
Paller, A. S., & Mancini, A. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24475-6.00024-8 · Cited by 21
Trimethylaminuria (Fish-Odor Syndrome): A Case Report
Arseculeratne, G., Wong, A. K. C., Goudie, D. R., & Ferguson, J. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.1.81 · Cited by 25
Winter, M., Bretschneider, T., Thamm, S., Kleiner, C., Grabowski, D., Chandler, S., Ries, R., Kley, J. T., Fowler, D., Bartlett, C., et al. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219838216 · Cited by 19
Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones
Henderson, M. C., Siddens, L. K., Krueger, S. K., Stevens, J. F., Kedzie, K. M., Fang, W., Heidelbaugh, T. M., Nguyen, P., Chow, K., Garst, M. E., et al. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.04.002 · Cited by 19
“Trimethylaminuria patients also exhibit altered metabolism of some drugs, suggesting expression of these FMO3 allelic variants could play a role in therapeutic efficacy and/or toxicity of certain drugs (Cashman et al., 2003; Shimizu et al., 2007).”
Clinical utility gene card for: Trimethylaminuria
Shephard, E. A., Treacy, E. P., & Phillips, I. R. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.214 · Cited by 22
Trimethylaminuria (fish odor syndrome): Genotype characterization among Portuguese patients
Ferreira, F. M. B., Esteves, S., Almeida, L. S., Gaspar, A. M. C., da Costa, C. D., Janeiro, P. C. R. B., Bandeira, A., Martins, E., Teles, E. L., Garcia, P., et al. (2013) · Gene · doi:10.1016/j.gene.2013.05.025 · Cited by 23
“…forms of TMAu including an acquired TMAu with no obvious FMO3 background, a transient childhood form, and a transient form in women associated with menstruation have been described (Cashman and Zhang, 2002; Cashman et al., 2003; Mitchell and Smith, 2001; Shimizu et al., 2007; Zhang et al., 2003).”
BackgroundInfluentialMartelli, A., Abate, F., Roggia, M., Benedetti, G., Caradonna, E., Calderone, V., Tenore, G. C., Cosconati, S., Novellino, E., & Stornaiuolo, M. (2025) · Antioxidants · doi:10.3390/antiox14050517 · Cited by 27
“…TMA crosses the intestinal barrier, is transported by the portal vein, and reaches the liver, where it is oxidized to TMAO by flavin-containing monooxygenase 3 (FMO3) [12] and FMO1 [13], two microsomal cytochromes whose transcription is modulated by bile acids and upregulated by cholestasis.”
D’Angelo, R., Scimone, C., Esposito, T., Bruschetta, D., Rinaldi, C., Ruggeri, A., & Sidoti, A. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-328 · Cited by 16
“It is an autosomal recessive disorder, but there are minor forms of TMAU including an acquired TMAU with no obvious FMO3 background, a transient childhood form, and a transient form in women associated with menstruation [5-7].”
BackgroundHomogeneous chemiluminescent assays for free choline in human plasma and whole blood
Adamczyk, M., Brashear, R. J., Mattingly, P. G., & Tsatsos, P. H. (2006) · Analytica Chimica Acta · doi:10.1016/j.aca.2006.07.020 · Cited by 16
Cashman, J. R., Lattard, V., & Lin, J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.2.222 · Cited by 15
Self-citationBouchemal, N., Ouss, L., Brassier, A., Barbier, V., Gobin, S., Hubert, L., de Lonlay, P., & Moyec, L. L. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1174-6 · Cited by 16
A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota
Gabr, M. T., Machalz, D., Pach, S., & Wolber, G. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00218f · Cited by 15
Trimethylamine deposition in the egg yolk from laying hens with different FMO3 genotypes
Wang, J., Wu, S., Zhang, H. J., Yue, H., Xu, L., Ji, F., Xu, L., & Qi, G. (2013) · Poultry Science · doi:10.3382/ps.2012-02313 · Cited by 18
Transient Massive Trimethylaminuria Associated with Food Protein–Induced Enterocolitis Syndrome
Miller, N. B., Beigelman, A., Utterson, E. C., & Shinawi, M. S. (2013) · JIMD Reports · doi:10.1007/8904_2013_238 · Cited by 17
“…and TMAO in the urine: a TMAO/ (TMA + TMAO) ratio (also known as FMO3 metabolic capacity) (Yamazaki et al. 2004) of <92 % and/ or a urinary concentration of free TMA of 18–20 mmol/mmol creatinine is diagnostic of TMAU (Mayatepek and Kohlmuller 1998; Mitchell and Smith 2001; Cashman et al. 2003).”
BackgroundBorbás, T., Zhang, J., Cerny, M. A., Likó, I., & Cashman, J. R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010827 · Cited by 13
“Because FMO3 is solely responsible for TMA N-oxygenation in vivo, mutations of FMO3 that cause defective TMA N-oxygenation lead to a rare metabolic disorder called trimethylaminuria (Dolphin et al., 1997; Cashman, 2002a; Cashman et al., 2003).”
BackgroundSelf-citationGabr, M. T., & Świderek, K. (2020) · ChemMedChem · doi:10.1002/cmdc.202000571 · Cited by 15
Trimethylamine-N-Oxide (TMAO) and Predicted Risk of Cardiovascular Events After Partial Nephrectomy
Zou, X., Xiong, L., Guo, Z., Li, Y., Kang, N., Liu, X., Xie, Y., Peng, Y., Liu, Y., Cai, X., et al. (2022) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2023.08.104 · Cited by 11
Living with trimethylaminuria and body and breath malodour: personal perspectives
Flaherty, C. C., Phillips, I. R., Janmohamed, A., & Shephard, E. A. (2024) · BMC Public Health · doi:10.1186/s12889-024-17685-w · Cited by 11
“Clinically, TMAU is diagnosed by measuring urinary excretion of TMA as the percent of total TMA (i.e., TMA plus TMAO) excreted as unmetabolized free TMA (TMA/TMA + TMAO) [6, 18].”
BackgroundMonoamine Oxidases and Flavin-Containing Monooxygenases
Cashman, J. R., & Motika, M. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00405-x · Cited by 9
Self-citationGawryś-Kopczyńska, M., Szudzik, M., Samborowska, E., Konop, M., Chabowski, D. S., Onyszkiewicz, M., & Ufnal, M. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1340166 · Cited by 8
Allerston, C. K., Høberg‐Vetti, H., Houge, G., Phillips, I. R., & Shephard, E. A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.06.002 · Cited by 8
Zhong, H., Luo, Y., Sun, J., Wang, C., Wang, Q., Gao, G., Zhang, K., Li, Q., Wang, H.-W., Li, J., et al. (2017) · Gene · doi:10.1016/j.gene.2017.08.023 · Cited by 7
“The disorder is called trimethylaminuria (TMAU; OMIM # 602079; http://www.ncbi.nlm.nih.gov/ omim/?term=602079), which is an autosomal recessive disease (Treacy et al. 1995, Cashman et al. 2003).”
BackgroundJames, K. L., Gertz, E., Kirschke, C. P., Allayee, H., Huang, L., Kable, M. E., Newman, J. W. I., Stephensen, C. B., & Bennett, B. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032074 · Cited by 8
“Other SNPs have been described to affect FMO3 activity and may have provided a more complete surrogate of FMO3 activity [39].”
BackgroundPractical Aspects of Flavin-Containing Monooxygenase-Mediated Metabolism
Cashman, J. R. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00316 · Cited by 8
Self-citationHeinzmann, S. S., Waldenberger, M., Peters, A., & Schmitt‐Kopplin, P. (2022) · Metabolites · doi:10.3390/metabo12100992 · Cited by 6
“27 s), a microbial breakdown product of choline [25] and cinnamoylglycine (δ 6.”
BackgroundMonoamine Oxidases and Flavin-Containing Monooxygenases
Cashman, J. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64091-6 · Cited by 6
Self-citationKoevary, S. B., Nussey, J., & Kern, T. S. (2007) · Optometry · doi:10.1016/j.optm.2007.01.010 · Cited by 6
Wang, H., Nandakumar, P., Ayele, F. T., Tayo, B. O., Ware, E. B., Gu, C. C., Lu, Y., Yao, J., Zhao, W., Smith, J. A., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0277-1 · Cited by 6
Buckley, A. M., Zaidan, S., Sweet, M. G., Ewin, D. J., Ratliff, J. G., Alkazemi, A., Birch, W. D., McAmis, A. M., & Neilson, A. P. (2025) · Metabolites · doi:10.3390/metabo15080552 · Cited by 4
Li, B., Yang, S., Ye, J.-R., Chu, S., Chen, N., & An, Z. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136222 · Cited by 4
Paller, A. S., & Mancini, A. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0412-9.00024-1 · Cited by 6
Flavin-containing Monooxygenases in the Brain and their Involvement in Neurodegeneration and Aging
Li, B., & An, Z. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00067 · Cited by 4
HAMID, X. W. M. A., Xi, W. A. N. G., Xiangdong, D. I. N. G., Chuduan, W. A. N. G., & Xingbo, Z. H. A. O. (2014) · Frontiers of Agricultural Science and Engineering · doi:10.15302/j-fase-2014034 · Cited by 2
“[23] found that in unaffected individuals, TMA composes 0 to 9% of total urinary trimethylamines (i.”
BackgroundWalter, J. H., Wevers, R. A., & Mayatepek, E. (2016) · Springer eBooks · doi:10.1007/978-3-662-49771-5_30 · Cited by 2
Genetic and dietary interactions of fishy-egg taint in brown-shelled laying hens
Ward, A. K. K. (2008) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 2
Primary trimethylaminuria syndrome: more than an unpleasant odor
Antoñanzas, J., Querol‐Cisneros, E., Alkorta‐Aranburu, G., Patiño‐García, A., & España, A. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16401 · Cited by 1
Disorders of Peptide and Amine Metabolism
Wevers, R. A., Mayatepek, E., & Walker, V. (2022) · Springer eBooks · doi:10.1007/978-3-662-63123-2_31 · Cited by 1
The intestinal microbiota in the mechanism of obesity and atherosclerosis
Gajos, A. (2014) · Postępy Nauk Medycznych
Exploring the cofactor-binding and biocatalytic properties of flavin-containing enzymes
Kopacz, M. (2014) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Ferreira, F. M. B., Almeida, L. S., Gaspar, A. M. C., da Costa, C. D., Janeiro, P. C. R. B., Bandeira, A., Martins, E., Teles, E. L., Garcia, P., Azevedo, L., et al. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Триметиламинурия (синдром на рибената миризма)
Мусурлиева, Н. (2017) · Редки болести и лекарства сираци · doi:10.36865/2017.v8i1.30
Gut Microbiota and Risk for Atherosclerosis: Current Understanding of the Mechanisms
Dutta, B., Biswas, C., Arya, R. K., & Rahaman, S. O. (2020) · Springer eBooks · doi:10.1007/978-3-030-47384-6_8 · Cited by 1
(2014) · CRC Press eBooks · doi:10.1201/b17423-69
Trimethylamine [MAK Value Documentation, 2004]
Arbeitsstoffe, D. F. S. S. Z. P. G., & Greim, H. (2014) · Wiley eBooks · doi:10.1002/3527600418.mb7550e3814
Chen, H. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6430-3_231-2
Trimethylamin [MAK Value Documentation in German language, 2004]
Arbeitsstoffe, D. F. S. S. Z. P. G., & Greim, H. (2012) · Wiley eBooks · doi:10.1002/3527600418.mb7550d0038
Metadata
- Authors
- Cashman, J., Camp, K., Fakharzadeh, S., Fennessey, P., Hines, R., Mamer, O., Mitchell, S., Preti, G., Schlenk, D., & Smith, R.
- Affiliations
- Human BioMolecular Research Institute (US)
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-04-01
- Volume
- 4
- Issue
- 2
- Pages
- 151-170
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2138685029
- Cited by
- 110
- References
- 3
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 12 · 2013: 6 · 2012: 4
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 59618, R01DK059618)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Polyamine Metabolism and Applications
- Keywords
- trimethylaminuria, FMO3, trimethylamine, trimethylamine N-oxide, choline, hypertension, plasma choline, dietary management, vitamin supplementation, pregnancy and lactation, body odor
- MeSH terms
- Animals, Clinical Trials as Topic, Diet, Genotype, Humans, Hypertension, Liver, Metabolic Diseases, Metabolism, Inborn Errors, Methylamines, Odorants, Oxygenases, Polymorphism, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.